


Raltegravir 1200 mg Once Daily versus 400 mg Twice Daily
ONCEMRK Trial

Raltegravir 1200 mg Once Daily versus 400 mg Twice Daily ONCEMRK: Study Design

Study Design: ONCEMRK STUDY


- **Background:** Randomized, double-blind, phase 3 trial in antiretroviral-naïve adults with HIV comparing raltegravir 1200 mg once-daily with raltegravir 400 mg twice-daily, both in combination with tenofovir DF-emtricitabine.
- **Inclusion Criteria (n = 797 received treatment)**
 - Age ≥ 18 years
 - Antiretroviral-naïve
 - HIV RNA $\geq 1,000$ copies/mL
- **Treatment Arms**
 - *Raltegravir 1200 mg QD + TDF-FTC
 - Raltegravir 400 mg BID + TDF-FTC



*The 1200 mg dose of raltegravir given as two 600 mg tablets

Raltegravir 1200 mg Once Daily versus 400 mg Twice Daily ONCEMRK: Result

Week 48: Virologic Response (non-completer = failure)



Raltegravir 1200 mg Once Daily versus 400 mg Twice Daily ONCEMRK: Conclusions

Conclusions: “A once daily raltegravir 1200 mg regimen was non-inferior compared with raltegravir 400 mg twice daily for initial treatment of HIV-1 infection. These results support the use of raltegravir 1200 mg once daily for first-line therapy.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

